Actelion Share Price

Stocks

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
22/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
15/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	+0.99%	-	-	0
WUXI APPTEC CO., LTD.	-1.90%	+3.12%	+81.70%	+110.88%	73.45B
ARGENX SE	+0.87%	+15.32%	+56.99%	+95.59%	62.99B
INSMED INCORPORATED	+1.71%	-1.22%	+2.71%	+501.29%	28.05B
WUXI BIOLOGICS (CAYMAN) INC.	+5.85%	+10.56%	+65.09%	+27.01%	25.42B
BIONTECH SE	+21.96%	+21.98%	+1.54%	+2.50%	23.3B
GENMAB A/S	+2.28%	+5.65%	+42.00%	-12.34%	19.45B
PHARMAESSENTIA CORPORATION	0.00%	-2.78%	+247.46%	+423.83%	18.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.87%	+5.23%	+28.31%	+550.59%	16.53B
EXELIXIS, INC.	+2.39%	+7.96%	+44.96%	+157.77%	13.16B
Average	+3.85%	+5.80%	+63.42%	+206.35%	31.17B
Weighted average by Cap.	+2.80%	+6.43%	+63.20%	+169.72%